Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of clostridium difficile infections in allogeneic stem cell transplant

ABSTRACT

Objective/background: Clostridium difficile infection [CDI] is a potential complication during hematopoietic stem cell transplantation [HSCT], and no specific recommendations exist regarding treatment of CDI in allogeneic SCT patients. Use of metronidazole and oral vancomycin has been associated with clinical failure. Fidaxomicin has previously been found noninferior to the use of oral vancomycin for the treatment of CDI, and no studies have compared the use of oral